Best Paper

Anno 2024 (i paper vincitori saranno pubblicati a breve)

• Categoria best paper under 40
• Categoria best paper nazionale 1
• Categoria best paper nazionale 2
• Categoria best paper internazionale

Anno 2023

• Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
• HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
• Genomics to select treatment for patients with metastatic breast cancer

Anno 2022

• Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
• Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
• Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
• Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis

Anno 2021

• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
• Fasting-mimicking diet and hormone therapy induce breast cancer regression (2020)

Anno 2020

• Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
• Trastuzumab Emtansine for Residual Invasive HER2- Positive Breast Cancer (NEJM 2019)
• PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Anno 2019

• Adjuvant anastrozole versus exemestane versus letrozole
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Anno 2017

• 2017 – In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
• 2017 – Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
• 2017 – Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Anno 2015

• 2015 – Measures of Outcome inMetastatic Breast Cancer: Insights From a Real-World Scenario
• 2015 – Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole- Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer
• 2015 – Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Anno 2014

• 2014 – Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Anno 2013

• 2013 – Comprehensive molecular portraits of human breast tumours

Anno 2012

• 2012 – Everolimus in Postmenopausal Hormone- Receptor–Positive Advanced Breast Cancer

Anno 2011

• 2011 – Current and emerging biomarkers in breast cancer: prognosis and prediction

Anno 2009

• 2009 – Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
• 2009 – Biological Processes Associated with Breast Cancer Clinical Outcome Depend on theMolecular Subtypes

Con il Patrocinio di:

Progetto realizzato da: